Actonel significantly reduced moderate and severe vertebral fractures

San Antonio, TX (September 20, 2002) A new analysis of scientific data presented at today's meeting of the American Society for Bone and Mineral Research (ASBMR) showed that a 5 mg dose of Actonel (risedronate sodium tablets) daily significantly reduced moderate and severe vertebral fracture risk by 70 percent within one year in postmenopausal women with osteoporosis. Furthermore, the significant effect on vertebral fracture risk was sustained over three years.

This analysis combined data from two large Actonel clinical trials, VERT-NA and VERT-MN, which included postmenopausal women with either one prevalent vertebral fracture and low bone mineral density (BMD), or with at least two prevalent vertebral fractures. The objective of this analysis was to compare the incidence of moderate or severe vertebral fracture at one year in women who received Actonel or placebo. Fracture severity was determined using the fracture severity scoring system developed by Harry Genant, M.D., Professor of Radiology, Medicine, Epidemiology and Orthopaedic Surgery at the University of California, San Francisco, an investigator and pioneer of the assessment method used in the analysis.

Recent studies show severity of prevalent vertebral fractures is a predictor of future vertebral and non-vertebral fracture risk; patients with more severe baseline vertebral fractures are more likely to experience subsequent vertebral and non-vertebral fractures. Therefore, reducing the incidence of moderate or severe vertebral fractures may help decrease the risk of future fractures.

"The ultimate goal of osteoporosis treatment is to prevent fractures," said Dr. Genant, "These new findings, combined with previous Actonel clinical data showing reductions in both risk of first vertebral fracture and multiple vertebral fractures, suggest that Actonel reduces fracture risk across a range of osteoporotic severity."

According to


Page: 1 2 3 4

Related biology news :

1. Rare mutations can significantly increase risk factor for heart disease
2. Cancer health risk significantly underestimated by EPAs ambient model estimates
3. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
4. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
5. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
6. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
7. Cognitive abilities increase significantly with time in most prematurely born children
8. Combining key ingredients of vegetarian diet cuts cholesterol significantly, says study
9. Pollen productionand allergiesmay rise significantly over next 50 years
10. Brain size in premature infants significantly smaller than full-term babies
11. Multicenter study shows Benecol spread significantly reduces cholesterol levels in patients taking statin drugs

Post Your Comments:

(Date:9/30/2015)... Fla. , Sept. 30, 2015  The U.S. ... month issued another key ruling in favor of ... that Korean fingerprint scanner company Suprema and its U.S. ... of 1930, a trade provision that declares it unlawful ... trade, by infringing two of Crossmatch,s patents, the 5,900,993 ...
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
(Date:9/24/2015)... NEW YORK , Sept. 24, 2015  EyeLock ... will be showcasing its award winning and latest technology ... Anaheim, California . EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA.   EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare ... announced today that it received de novo clearance from the U.S. Food and ... the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound ...
(Date:10/12/2015)... Calif. and BRUSSELS , Oct. ... (Euronext Brussels: UCB) today presented additional findings from an exploratory ... The findings were presented today in an oral plenary ... (ASBMR) 2015 Annual Meeting in Seattle . ... --> The small exploratory sub-study data showed ...
(Date:10/12/2015)... 12, 2015  Rebiotix Inc. today announced that ... its lead Microbiota Restoration Therapy (MRT) RBX2660 as ... Clostridium difficile (C diff) infection, a ... 29,000 deaths in the U.S. annually. 1 ... was founded to revolutionize the treatment of debilitating ...
(Date:10/12/2015)... SAN DIEGO , Oct. 12, 2015 /PRNewswire/ ... for debilitating allergic and inflammatory diseases and conditions, ... Series A preferred stock financing. Concurrent with the ... also entered into a Loan and Security Agreement ... borrow up to $7 million. Patara will use ...
Breaking Biology Technology:
Cached News: